Develops drugs for pulmonary arterial hypertension and neuroblastoma.
Jun 2026Revenue $3.15B/yrExpenses $1.75B/yr
No trend
Figures by year
Is UNITED THERAPEUTICS profitable?
Yes. In the 12 months to Jun 2026, revenue was $3.15B and expenses $1.75B.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $3.18B | $1.69B | $1.49B |
| Dec 2024 | $2.88B | $1.50B | $1.38B |
| Dec 2023 | $2.33B | $1.14B | $1.18B |
| Dec 2022 | $1.94B | $957M | $980M |
| Dec 2021 | $1.69B | $1.13B | $556M |
| Dec 2020 | $1.48B | $890M | $594M |
| Dec 2019 | $1.45B | $1.64B | −$188M |
| Dec 2018 | $1.63B | $822M | $805M |
| Dec 2017 | $1.73B | $910M | $815M |
| Dec 2016 | $1.60B | $537M | $1.06B |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.